IDXX - IDEXX Laboratories, Inc.
After hours:
| Previous close | 469.84 |
| Open | 471.86 |
| Bid | 465.00 x 800 |
| Ask | 482.00 x 800 |
| Day's range | 467.32 - 478.30 |
| 52-week range | 317.06 - 515.79 |
| Volume | |
| Avg. volume | 390,558 |
| Market cap | 39.081B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | 55.85 |
| EPS (TTM) | 8.43 |
| Earnings date | 31 Jul 2023 - 04 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 559.67 |
ZacksIdexx (IDXX) Down 2.9% Since Last Earnings Report: Can It Rebound?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Simply Wall St.IDEXX Laboratories (NASDAQ:IDXX) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Simply Wall St.
Investing in IDEXX Laboratories (NASDAQ:IDXX) five years ago would have delivered you a 146% gain
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Business WireIDEXX Laboratories to Present at Stifel Conference and Announces 2023 Investor Day
WESTBROOK, Maine, May 10, 2023--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in the Stifel Jaws & Paws Conference on Wednesday, May 31, 2023. Jay Mazelsky, President and Chief Executive Officer, and Brian McKeon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at 1:15 pm (EDT).
Motley Fool3 Best Stocks to Buy in May and Hold Forever
In need of healthcare exposure in your portfolio? Consider holding these three promising companies forever.
- Simply Wall St.
At US$488, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?
Let's talk about the popular IDEXX Laboratories, Inc. ( NASDAQ:IDXX ). The company's shares received a lot of attention...
ZacksIDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase
Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.
ZacksCompared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksIdexx Laboratories (IDXX) Q1 Earnings and Revenues Beat Estimates
Idexx (IDXX) delivered earnings and revenue surprises of 7.14% and 1.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireIDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine, May 02, 2023--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results.
Motley FoolWhy These 2 Vet Med Stocks Are Surging
Over the past decade, spending on veterinary care has tripled in the United States. The growth in that spending makes veterinary care stocks somewhat recession proof. More and more, spending on pet healthcare is seen as something people need rather than want.
ZacksWill Alphatec (ATEC) Report Negative Earnings Next Week? What You Should Know
Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksIdexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
ZacksAmerisourceBergen's (ABC) New JV to Boost Oncology Care
AmerisourceBergen's (ABC) new JV is expected to provide the independent community oncology network with additional resources and expertise to grow the platform and improve patient outcomes.
ZacksIDEXX Laboratories (IDXX) to Post Q1 Earnings: What's in Store?
IDEXX Laboratories' (IDXX) first-quarter 2023 results are expected to reflect an impressive performance in the CAG segment despite inflationary impacts.
ZacksZimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?
Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.
- Zacks
Masimo's (MASI) New FDA Approval to Improve Patient Monitoring
Masimo's (MASI) receipt of the FDA's clearance for the Rad-G with Temperature is expected to support clinicians in almost any care scenario.
Zacks3 Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
- Simply Wall St.
Those who invested in IDEXX Laboratories (NASDAQ:IDXX) five years ago are up 143%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Business WireIDEXX Laboratories to Release 2023 First Quarter Financial Results
WESTBROOK, Maine, April 13, 2023--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 first quarter results for Tuesday, May 2, 2023 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
ZacksALC vs. IDXX: Which Stock Is the Better Value Option?
ALC vs. IDXX: Which Stock Is the Better Value Option?
ZacksHere's Why You Should Invest in IDEXX (IDXX) Stock Right Now
Investors are optimistic about IDEXX's (IDXX) strength in the Companion Animal Group business.
- Simply Wall St.
What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
IDEXX Laboratories, Inc. ( NASDAQ:IDXX ) saw a double-digit share price rise of over 10% in the past couple of months...
- Simply Wall St.
These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...